Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Portfolio Pulse from Lara Goldstein
Clinical-stage biopharma company atai Life Sciences (NASDAQ:ATAI) has completed its Phase 1 study of proprietary oral transmucosal film (OTF) DMT formulation VLS-01 in 74 healthy participants. The study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of VLS-01. The results showed that the compound was well-tolerated with a favorable safety profile. The company now plans to test an optimized version of its OTF formulation in an upcoming Phase 1b trial before initiating a Phase 2 in Treatment-Resistant Depression patients.
October 03, 2023 | 7:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
atai Life Sciences has completed a Phase 1 study for its DMT formulation VLS-01, with positive results. The company plans to proceed with further trials, which could potentially lead to a new treatment option for Treatment-Resistant Depression.
The successful completion of the Phase 1 study for atai Life Sciences' DMT formulation VLS-01 is a positive development for the company. The favorable safety profile and well-tolerated nature of the compound suggest that it has potential as a treatment option. The company's plans to proceed with further trials indicate confidence in the product, which could have a positive impact on the company's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100